Health Trials

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

ConditionGram-negative Bacteremia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJohns Hopkins University

About this trial

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.

Eligibility criteria

Qualifiers

Adult (≥ 18 years) at the time of screening

Hospitalized

Identification of at least one Gram-negative organism in a blood culture

Capable of providing written informed consent (includes through a legally authorized representative)

Disqualifiers

Unable to tolerate or absorb a course of oral antibiotics

Actively receiving vasopressors

Gram-negative organism not susceptible to any oral antibiotics

Gram-negative organism not susceptible to any IV antibiotics

Trial design

Treatments tested in this trial

  • Intravenous Antibiotics
  • Oral Antibiotics

Treatment groups

1,030 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Johns Hopkins University

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator

Source ClinicalTrials.gov